Surgery Partners (NASDAQ: SGRY) operates a comprehensive network of surgical facilities across the United States, a key player in the dynamic healthcare sector. The company partners with physicians to provide essential surgical services in various specialties. As part of the competitive Medical Services industry, Surgery Partners strategically focuses on outpatient procedures, which are medical treatments that do not require an overnight hospital stay for the patient, enhancing efficiency and patient convenience.
Reflecting a positive investment outlook, analyst Sarah James from Raymond James sets a price target of $18.00 for Surgery Partners. When this target was issued, the stock was trading at $15.34. This represents a potential upside, or increase in value, of 17.34% from that price, suggesting strong confidence in the company's future stock performance and growth trajectory.
This optimism is further supported by the company's recent financial results. For its second quarter of 2026, Surgery Partners reported revenues of $848.90 million, which was higher than the analyst consensus estimate of $830.03 million. This impressive revenue figure also shows a 2.7% increase compared to the same quarter in the previous year, indicating solid revenue growth.
The company also performed exceptionally well in its profitability. Surgery Partners announced earnings per share (EPS) of $0.10, significantly surpassing the expected $0.06. EPS, a crucial indicator of a company's profit per outstanding share of stock, highlights strong quarterly earnings, although it is lower than the $0.17 EPS from the prior year's quarter.
Looking at other key financial indicators, Surgery Partners' adjusted EBITDA was approximately $125.00 million for the quarter. EBITDA is a vital measure of profitability before non-operating expenses. The company also reported a positive return on equity of 1.04%.
